MAKE POST GRADUATION exam oriented emergency medicine with topic name COMMUNITY ACQUIRED PNEUMONIA WITH REFFERENCE TINTILATY AND HARRISON BASED REFER
Reading File
Finding Sources
Finding Sources
Searching PubMed
"community-acquired pneumonia"[MeSH Terms] AND "guidelines"[pt]
Finding Sources
Reading File
Searching PubMed
"community-acquired pneumonia" AND management
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
🫁 COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Post-Graduate Exam Oriented Emergency Medicine Notes
References: Tintinalli's Emergency Medicine (9th Ed) | Harrison's Principles of Internal Medicine (22nd Ed, 2025)
1. DEFINITION & EPIDEMIOLOGY
Definition (Tintinalli, Chapter 65):
CAP = Acute pulmonary infection in a patient who is not hospitalized or residing in a long-term care facility for ≥14 days before presentation.
| Classification | Criteria |
|---|---|
| CAP | Not hospitalized or in LTCF ≥14 days before |
| HAP | New infection ≥48 h after hospital admission |
| VAP | New infection ≥48 h after endotracheal intubation |
| HCAP | Hospitalized ≥2 days in past 90 days, nursing home resident, home IV antibiotics, dialysis, chronic wound care, chemotherapy, immunocompromised |
Key epidemiologic facts (Harrison's 22E, Chapter 131):
- ~7 million CAP cases/year in the United States
- Incidence: 16-23 per 1000 adults; hospitalization rate: 650/100,000 (rises to 2000/100,000 in elderly)
- ~30% of patients require hospitalization (~1.5 million admissions/year)
- Outpatient mortality: <5%; Hospitalized: 12-40% depending on ICU status
- #1 cause of infection-related death in patients >65 years (Harrison's)
- 18% of hospitalized CAP patients are readmitted within 1 month
- Annual cost: ~$17 billion
2. PATHOPHYSIOLOGY
Route of infection (Tintinalli):
- Primary route: Aspiration of oropharyngeal secretions (most common)
- Inhalation of aerosolized organisms
- Hematogenous seeding (S. aureus, Pneumococcus)
Risk factors - HIGH-YIELD TABLE (Tintinalli):
| Category | Examples |
|---|---|
| Aspiration risk | Stroke, dysphagia, seizure, syncope, nasogastric tube, intubation, esophageal motility disorders |
| Bacteremia risk | Indwelling vascular devices, intrathoracic devices, debilitation |
| Immune compromise | Extremes of age, alcoholism, HIV, malignancy |
| Mucociliary clearance impairment | Smoking, COPD, bronchiectasis |
3. MICROBIOLOGY - CAUSATIVE ORGANISMS
Typical vs. Atypical Pathogens
| Typical Bacteria | Atypical Organisms |
|---|---|
| Streptococcus pneumoniae (#1 overall) | Mycoplasma pneumoniae |
| Haemophilus influenzae | Chlamydia pneumoniae (now <1% of CAP) |
| Klebsiella pneumoniae | Legionella species |
| Staphylococcus aureus | Respiratory viruses (influenza, RSV, parainfluenza, hMPV, SARS-CoV-2) |
| Gram-negative bacilli | Coxiella burnetii (Q fever) |
Site-of-Care Based Pathogens (Harrison's Table 131-1) - VERY HIGH YIELD
| Outpatients | Non-ICU Inpatients | ICU Inpatients |
|---|---|---|
| S. pneumoniae | S. pneumoniae | S. pneumoniae |
| Mycoplasma pneumoniae | Mycoplasma pneumoniae | Staphylococcus aureus |
| H. influenzae | C. pneumoniae | Legionella spp. |
| C. pneumoniae | H. influenzae | Gram-negative bacilli |
| Respiratory viruses | Legionella spp. | H. influenzae |
| - | Respiratory viruses | Respiratory viruses |
Epidemiologic Clues to Specific Pathogens (Harrison's Table 131-2) - EXAM FAVORITE
| Exposure/Risk Factor | Organism to Suspect |
|---|---|
| Alcoholism | S. pneumoniae, oral anaerobes, Klebsiella, Acinetobacter, TB |
| COPD/Smoking | H. influenzae, Pseudomonas, Legionella, S. pneumoniae, M. catarrhalis |
| Structural lung disease (bronchiectasis) | Pseudomonas, Burkholderia cepacia, S. aureus |
| Dementia, stroke, decreased consciousness | Oral anaerobes, gram-negative enteric bacteria |
| Lung abscess | CA-MRSA, oral anaerobes, endemic fungi, TB |
| Hotel/cruise ship stay (past 2 weeks) | Legionella spp. |
| Bird exposure | Histoplasma capsulatum, Chlamydia psittaci |
| Rabbit exposure | Francisella tularensis |
| Sheep/goats/parturient cats | Coxiella burnetii (Q fever) |
| Ohio/St. Lawrence River Valley travel | Histoplasma capsulatum |
| Southwestern USA travel | Hantavirus, Coccidioides spp. |
| Southeast Asia travel | Burkholderia pseudomallei, avian influenza |
4. CLINICAL PRESENTATION
Classic symptoms: Fever, cough (productive or dry), pleuritic chest pain, dyspnea, rigors
Signs: Tachypnea, tachycardia, consolidation signs - dullness to percussion, bronchial breath sounds, egophony, whispered pectoriloquy, crackles/rales
Atypical presentations (Tintinalli - high yield):
- Elderly: Falls, weakness, delirium/confusion, functional decline, GI symptoms - may lack classic fever or leukocytosis
- Immunocompromised: Subtle, minimal symptoms
- Up to 1/3 of elderly with CAP will NOT have leukocytosis
Poor prognostic signs in elderly: Hypothermia OR temp >38.3°C, leukopenia, immunosuppression, gram-negative/staphylococcal infection, cardiac disease, bilateral infiltrates, extrapulmonary disease
5. DIAGNOSIS
Chest X-ray (gold standard for diagnosis): Infiltrate/consolidation confirmation required. CXR findings may lag 24-48 hours behind clinical symptoms in dehydrated patients.
Lab workup based on site of care (Tintinalli/IDSA 2017):
- Mild outpatient: No ancillary testing necessary in healthy patients
- If admission required: CBC, BMP (electrolytes, BUN, Cr, glucose), consider ABG if severe desaturation
- Blood cultures: Recommended for ICU patients, leukopenia, cavitary lesions, severe liver disease, alcoholism, asplenia, pleural effusions
- Sputum cultures: Value similar to blood cultures; >80% of cases yield no additional information
- Positive blood culture rate increases with illness severity (higher in ICU CAP)
- Urinary antigen tests: For Legionella and S. pneumoniae in severe/ICU CAP
- PCR: Increasingly used for viral detection; viruses found in 20-30% of CAP patients
6. SEVERITY SCORING - HIGHEST YIELD TOPIC FOR PG EXAMS
A. CURB-65 Score (Harrison's & Tintinalli)
| Letter | Parameter | Points |
|---|---|---|
| C | Confusion (new onset) | 1 |
| U | Urea (BUN) >7 mmol/L (>19 mg/dL) | 1 |
| R | Respiratory rate ≥30/min | 1 |
| B | Blood pressure - systolic ≤90 mmHg OR diastolic ≤60 mmHg | 1 |
| 65 | Age ≥65 years | 1 |
Management by score:
| CURB-65 Score | 30-day Mortality | Recommendation |
|---|---|---|
| 0 | 1.5% | Outpatient |
| 1-2 | ~8% | Hospitalize (unless due solely to age ≥65) |
| ≥3 | 22% | Hospitalize; consider ICU |
B. Pneumonia Severity Index (PSI) / PORT Score (Tintinalli Table 65-12)
- 20 variables including age, comorbidities, physical exam, labs
- More accurate and robustly validated than CURB-65 but more complex to calculate
- PSI identifies low-risk patients - helps AVOID unnecessary admissions
| PSI Class | Points | Mortality | Recommendation |
|---|---|---|---|
| I | No predictors | 0.1% | Outpatient |
| II | <70 | 0.6% | Outpatient |
| III | 71-90 | 2.8% | Individualized (consider observation) |
| IV | 91-130 | 8.2% | Inpatient |
| V | >130 | 29.2% | Inpatient |
Key distinction: PSI better for identifying LOW-risk patients; CURB-65 is simpler
C. ATS/IDSA Criteria for Severe CAP (ICU Admission) - Harrison's Table 131-3
Major criteria (either one = ICU):
- Septic shock requiring vasopressors
- Acute respiratory failure requiring intubation/mechanical ventilation
Minor criteria (≥3 = ICU or high-level monitoring):
- Respiratory rate ≥30 breaths/min
- PaO2/FiO2 ratio ≤250
- Multilobar infiltrates
- Confusion/disorientation
- Uremia (BUN ≥20 mg/dL)
- Leukopenia (WBC <4000 cells/µL)
- Thrombocytopenia (platelets <100,000/µL)
- Hypothermia (core temp <36°C)
- Hypotension requiring aggressive fluid resuscitation
7. TREATMENT
Outpatient Therapy (Tintinalli + Harrison's)
| Patient Type | First-Line Drug | Alternative |
|---|---|---|
| Healthy, no comorbidities, no recent antibiotics | Macrolide (azithromycin 500 mg day 1, then 250 mg days 2-5; OR clarithromycin XL 1000 mg/day x7d) | Doxycycline 100 mg BID x 10-14 days |
| With comorbidities (COPD, DM, heart/renal/liver disease, alcoholism, immunosuppression) | Respiratory fluoroquinolone (levofloxacin 750 mg/day OR moxifloxacin 400 mg/day) | Beta-lactam + macrolide |
| Recent antibiotics in past 3 months (risk of resistance) | Respiratory fluoroquinolone OR beta-lactam + macrolide | - |
Note: CDC recommends reserving fluoroquinolones for those who cannot tolerate other agents, documented pneumococcal resistance, or failure of other therapies. Do NOT give fluoroquinolones to patients with myasthenia gravis.
Inpatient (Non-ICU) Therapy (Tintinalli Table 65-6 + Harrison's Table 131-5)
| Drug Class | Drug | Dose |
|---|---|---|
| Respiratory fluoroquinolone | Levofloxacin | 750 mg IV/PO |
| Respiratory fluoroquinolone | Moxifloxacin | 400 mg IV/PO |
| OR: 3rd-gen cephalosporin + macrolide | Ceftriaxone 1-2 g IV/day + azithromycin 500 mg IV/day | - |
| Alternative beta-lactams | Ampicillin-sulbactam, cefotaxime, ceftaroline, ertapenem | - |
Inpatient (ICU) Therapy (Harrison's Table 131-5)
| Risk Stratification | Regimen |
|---|---|
| No MRSA/Pseudomonas risk factors | Beta-lactam + macrolide OR beta-lactam + respiratory fluoroquinolone |
| Prior respiratory isolation of MRSA or P. aeruginosa | Add coverage for MRSA (vancomycin 15 mg/kg q12h, or linezolid 600 mg q12h) OR P. aeruginosa (piperacillin-tazobactam, cefepime, meropenem) |
| Recent hospitalization + antibiotics ± local validation | Add MRSA or Pseudomonas coverage if cultures positive |
Beta-lactams options for ICU: ampicillin-sulbactam (1.5-3 g q6h), ceftriaxone (1-2 g/day), cefotaxime (1-2 g q8h), ceftaroline (600 mg q12h), ertapenem (1 g/day)
Macrolides: Azithromycin 500 mg/day OR clarithromycin 500 mg BID
Respiratory FQs: Levofloxacin 750 mg/day, moxifloxacin 400 mg/day, gemifloxacin 320 mg/day
Newer Agents (Harrison's 22E, 2025)
- Lefamulin (pleuromutilin) - option for patients unable to take beta-lactams/fluoroquinolones
- Omadacycline (tetracycline) - similar indication; available in USA but not Canada
8. SPECIAL POPULATIONS
Elderly (Tintinalli)
- Most common infection in elderly = pneumonia; 5th leading cause of death in elderly
- Incidence: 25-44/1000 in general elderly population; mortality up to 40%
- 3x more likely to have pneumococcal bacteremia than younger patients
- Mortality from pneumococcal pneumonia: 3-5x greater (up to 40%) vs. age <65
- Atypical presentation: confusion, falls, functional decline, GI symptoms
- Up to 1/3 lack leukocytosis
Nursing Home Patients (Tintinalli)
- 2nd leading cause of infection in nursing homes (after UTI)
- Leading cause of transfer to hospital AND leading cause of death in nursing homes
- Key predictors: tachycardia, RR ≥30, temp ≥38°C, somnolence, confusion, crackles, leukocytosis
- Pathogens: S. pneumoniae, gram-negative bacilli, H. influenzae
- Treat for HCAP organisms including MRSA coverage
Pregnant Women (Tintinalli)
- Particularly susceptible to severe influenza-associated pneumonia
- Antivirals recommended for pregnant women with influenza-like illness
- Varicella pneumonia also severe in pregnancy - antivirals recommended
HIV/Immunocompromised
- Consider PCP (Pneumocystis jirovecii) - CD4 <200
- Also consider: TB, fungal pneumonias, CMV in severely immunosuppressed
- Reduced pneumococcal response to infection
9. ANTIBIOTIC RESISTANCE (Harrison's 22E)
- Main resistance issues in CAP: S. pneumoniae and CA-MRSA
- Pneumococcal resistance to beta-lactams: acquired through DNA incorporation and remodeling of penicillin-binding proteins
- Macrolide resistance: now >25% in many areas (clinically significant)
- Macrolide monotherapy NOT recommended if local resistance ≥25%
- With increasing pneumococcal vaccine use, incidence of pneumococcal pneumonia is decreasing
10. HIGH-YIELD MNEMONICS & MEMORY AIDS
CURB-65 Mnemonic
Confused, Urea high, Respiratory rate fast, Blood pressure low, age 65+
"SICKLE" - Indications for Blood Cultures in CAP
S - Severe disease (ICU)
I - Immunocompromised (asplenia, HIV)
C - Cavitary lesions
K - (a)Lcohol abuse (leukopenia)
L - Liver disease (severe)
E - Effusion (pleural)
Key Numbers to Memorize
- CAP definition: Patient NOT in hospital/LTCF for ≥14 days
- HAP/VAP: New infection ≥48 hours after admission/intubation
- CURB-65 score ≥3: mortality 22%
- PSI Class V: mortality 29.2%
- Elderly: up to 1/3 lack leukocytosis
- ICU minor criteria: need ≥3 of 9 criteria
- PaO2/FiO2 ratio cutoff for ICU: ≤250
- Aspiration risk in healthy sleeping adults: ~50%
11. PG EXAM MCQs (RECALLED / EXAM-TYPE)
Q1. A 70-year-old male with confusion, BUN 25 mg/dL, RR 32/min, BP 100/70 mmHg presents with productive cough and fever. His CURB-65 score is:
- A) 2
- B) 3
- C) 4
- D) 5
Answer: C - 4 (Confusion=1, Urea elevated >7 mmol/L=1, RR ≥30=1, Age ≥65=1; BP not low enough to score)
Q2. As per ATS/IDSA criteria, which of the following is a MAJOR criterion for severe CAP requiring ICU admission?
- A) Multilobar infiltrates
- B) PaO2/FiO2 ≤250
- C) Septic shock requiring vasopressors
- D) BUN ≥20 mg/dL
Answer: C - Septic shock requiring vasopressors is a major criterion (any one major = ICU). The rest are minor criteria.
Q3. A 35-year-old software engineer returns from a 2-week stay at a luxury hotel in Europe with fever, dry cough, hyponatremia, diarrhea, and confusion. CXR shows patchy infiltrates. Most likely organism?
- A) Mycoplasma pneumoniae
- B) Streptococcus pneumoniae
- C) Legionella pneumophila
- D) Chlamydia pneumoniae
Answer: C - Hotel/cruise ship stay + hyponatremia + GI symptoms + CNS involvement = Legionella (Harrison's Table 131-2)
Q4. An elderly alcoholic patient presents with cavitary pneumonia in the right upper lobe. Most likely organism?
- A) Pneumococcus
- B) CA-MRSA
- C) Klebsiella pneumoniae
- D) Legionella
Answer: B - Lung abscess and cavitary lesions: CA-MRSA, oral anaerobes, endemic fungi, TB (Harrison's Table 131-2). Klebsiella classically causes upper lobe cavitary disease in alcoholics with "currant jelly sputum" but MRSA is the listed organism for cavitary/lung abscess in Harrison's table.
Q5. First-line outpatient treatment for a healthy 30-year-old with CAP, no comorbidities, no recent antibiotic use:
- A) Amoxicillin-clavulanate
- B) Azithromycin
- C) Levofloxacin
- D) Ceftriaxone IV
Answer: B - Macrolide (azithromycin) is first-line for outpatient CAP without comorbidities or recent antibiotics (Tintinalli + Harrison's)
Q6. Number of ATS/IDSA minor criteria needed to indicate ICU-level care in CAP:
- A) 1
- B) 2
- C) 3
- D) 5
Answer: C - ≥3 minor criteria = admit to ICU or high-level monitoring unit (Harrison's)
Q7. Which PSI class has the highest mortality in pneumonia requiring inpatient treatment?
- A) Class III - 2.8%
- B) Class IV - 8.2%
- C) Class V - 29.2%
- D) Class II - 0.6%
Answer: C - PSI Class V (>130 points) has 29.2% mortality
Q8. According to Tintinalli, approximately what percentage of pneumonia cases in the U.S. result in hospitalization?
- A) 10%
- B) 20%
- C) 30%
- D) 50%
Answer: C - ~30% of CAP cases require hospitalization (~1.5 million admissions/year)
Q9. A patient with COPD on home oxygen is admitted with CAP. She received clarithromycin 3 months ago. Most appropriate empiric therapy?
- A) Azithromycin monotherapy
- B) Respiratory fluoroquinolone (levofloxacin)
- C) Doxycycline
- D) Amoxicillin alone
Answer: B - Respiratory fluoroquinolone OR beta-lactam + macrolide for patients with comorbidities and recent antibiotic use (Tintinalli, Harrison's)
Q10. Fluoroquinolones are contraindicated for CAP treatment in which condition?
- A) Renal failure
- B) Myasthenia gravis
- C) Atrial fibrillation
- D) Peptic ulcer disease
Answer: B - Tintinalli explicitly states: "Do not give fluoroquinolones to patients with myasthenia gravis."
12. SUMMARY TABLE - HIGH-YIELD QUICK REVIEW
| Topic | Key Fact |
|---|---|
| #1 cause of CAP | S. pneumoniae |
| ICU CAP - additional organisms vs. non-ICU | Staphylococcus aureus, Legionella, GNB (Harrison) |
| #1 route of infection | Aspiration |
| Legionella clue | Hotel/cruise ship + hyponatremia + diarrhea |
| CURB-65 ≥3 | 22% mortality, hospitalize/consider ICU |
| PSI Class V | 29.2% mortality |
| ICU: 2 major criteria | Vasopressors, mechanical ventilation |
| ICU: minor criteria | ≥3 of 9 (RR≥30, PaO2/FiO2 ≤250, multilobar, confusion, BUN≥20, WBC<4000, plts<100k, temp<36°C, hypotension) |
| Outpatient 1st line | Macrolide (azithromycin) |
| Outpatient with comorbidities | Respiratory fluoroquinolone |
| Inpatient non-ICU | FQ alone OR ceftriaxone + azithromycin |
| Inpatient ICU | Beta-lactam + macrolide OR beta-lactam + FQ |
| MRSA coverage | Vancomycin or linezolid |
| Pseudomonas coverage | Pip-tazo, cefepime, meropenem |
| Myasthenia gravis | AVOID fluoroquinolones |
| Elderly - leukocytosis | Absent in 1/3 of elderly CAP |
| HAP definition | New infection ≥48h after admission |
| CAP definition | Not in hospital/LTCF for ≥14 days before |
2026 Update: The ATS 2026 Clinical Practice Guideline for CAP (PMID 40679934) was published in January 2026 in the American Journal of Respiratory and Critical Care Medicine. It may include updated antibiotic recommendations - check for the latest IDSA/ATS guidance for your exams.
References:
- Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 9th Ed., Chapter 65 (Pneumonia)
- Harrison's Principles of Internal Medicine, 22nd Ed. (2025), Chapter 131 (Community-Acquired Pneumonia)
This is a shared conversation. Sign in to Orris to start your own chat.